Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Renny Abraham

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
BiomarkersVijay Benade, Anil Shinde, Rajesh Kumar Badange, et al.
International Journal of Geriatric Psychiatry|September 28, 2022
Potential beneficial effects of masupirdine (SUVN-502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analysesRamakrishna Nirogi, Pradeep Jayarajan, Vijay Benade, et al.
European Journal of Pharmacology|March 30, 2023
Usmarapride (SUVN-D4010), a 5-HT<sub>4</sub> receptor partial agonist for the potential treatment of Alzheimer's disease: Behavioural, neurochemical and pharmacological profilingRamakrishna Nirogi, Venkata Ramalingayya Grandhi, Rajeshbabu Medapati, et al.
Sleep Medicine|November 6, 2024
Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist: Results from the phase 2 double-blind randomized placebo-controlled study for the treatment of excessive daytime sleepiness in adult patients with narcolepsyRamakrishna Nirogi, Anil Shinde, Vinod Kumar Goyal, et al.
Psychopharmacology|March 17, 2022
Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterizationRamakrishna Nirogi, Renny Abraham, Pradeep Jayarajan, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentRenny Abraham, Venkatesh Goura, Rajesh Kallepalli, et al.
Journal of Medicinal Chemistry|July 12, 2021
Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT<sub>4</sub> Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer's DiseaseRamakrishna Nirogi, Abdul Rasheed Mohammed, Anil Karbhari Shinde, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
BiomarkersVijay Benade, Anil Shinde, Rajesh Kumar Badange, et al.
International Journal of Geriatric Psychiatry|September 28, 2022
Potential beneficial effects of masupirdine (SUVN-502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analysesRamakrishna Nirogi, Pradeep Jayarajan, Vijay Benade, et al.
European Journal of Pharmacology|March 30, 2023
Usmarapride (SUVN-D4010), a 5-HT<sub>4</sub> receptor partial agonist for the potential treatment of Alzheimer's disease: Behavioural, neurochemical and pharmacological profilingRamakrishna Nirogi, Venkata Ramalingayya Grandhi, Rajeshbabu Medapati, et al.
Sleep Medicine|November 6, 2024
Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist: Results from the phase 2 double-blind randomized placebo-controlled study for the treatment of excessive daytime sleepiness in adult patients with narcolepsyRamakrishna Nirogi, Anil Shinde, Vinod Kumar Goyal, et al.
Psychopharmacology|March 17, 2022
Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterizationRamakrishna Nirogi, Renny Abraham, Pradeep Jayarajan, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentRenny Abraham, Venkatesh Goura, Rajesh Kallepalli, et al.
Journal of Medicinal Chemistry|July 12, 2021
Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT<sub>4</sub> Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer's DiseaseRamakrishna Nirogi, Abdul Rasheed Mohammed, Anil Karbhari Shinde, et al.
Pageof 3